Why it matters
AI adoption increasingly requires a post-deployment evidence and monitoring architecture, not only premarket validation.
Decision implication
Add real-world monitoring, drift detection, human-AI interaction, and response protocols to P4L's AI adoption/evidence standard.
Who or what is affected
- FDA
- AI medical-device developers
- hospitals
- clinicians
- quality teams
- patients
Evidence and sources
Decision priority: Watch
Source authority: Primary/authoritative · official FDA source
Evidence design: Program record
Applicability: Direct
Confidence for the stated claim: High
Freshness: Historical
P4L distinguishes the sourced record from interpretation. Program inclusion, participation, funding, proposal status, or a public listing does not by itself establish clinical effectiveness, endorsement, coverage, or scaled adoption unless the cited source specifically establishes it.
For this decision
Clinicians · Innovators · Health-system leaders · Policymakers
What P4L is watching next
- New guidance
- postmarket requirements
- performance-monitoring standards
- drift methodologies.
Related proof records
None recorded.
Record provenance
- Last verified
- 2026-09-03
- Source updated
- 2025-09-30
- Revision state
- Version 1.1 corrects the observation date to September 30, 2025, recasts the item as a closed discussion-only request rather than current guidance or policy, and records the September 3, 2026 re-verification.
- Status
- Closed 2025 request for comment · discussion only · not guidance or policy
- Freshness
- Historical
- Version
- 1.1
- Stable ID
- SIG-2026-010